Evidence map›Paper›PMID 39174553›Full record

ArticleNature communications2024

Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection.

Sung Hee Ko, Pierce Radecki, Frida Belinky, Jinal N Bhiman, Susan Meiring, Jackie Kleynhans, Daniel Amoako, Vanessa Guerra Canedo, Margaret Lucas, Dikeledi Kekana and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Sung Hee Ko *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-4678-7449
Pierce Radecki *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-1103-5327
Frida BelinkyVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jinal N BhimanNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0001-6354-4003
Susan MeiringNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0003-4508-5469
Jackie KleynhansNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0001-7081-6273
Daniel AmoakoNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0003-3551-3458
Vanessa Guerra CanedoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Margaret LucasVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0009-0003-4147-1896
Dikeledi KekanaNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.
Neil MartinsonPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Limakatso LebinaPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Josie EverattNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.
Stefano TempiaNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0003-4395-347X
Tatsiana BylundVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Reda RawiVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-0445-2325
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-3560-232X
Nicole WolterNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0002-9526-0133
Anne von GottbergNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0002-0243-7455
Cheryl CohenNational Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0003-0376-2302
Eli A BoritzVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. eli.boritz@niaid.nih.gov.ORCID 0000-0003-4633-4594

Funding

Mechanisms Of Humoral EvasionZIAAI005023 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$18.6M
Computational Tools for Structural AnalysisZICAI005112 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RAWI, REDA · 2010 to 2025
$4.1M
Persistence and Evolution of SARS-CoV-2ZIAAI005157 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BORITZ, ELI · 2020 to 2025
$1.3M
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI005157Wellcome Trust
6 · The paper itself

Abstract

Previous studies have linked the evolution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic variants to persistent infections in people with immunocompromising conditions, but the processes responsible for these observations are incompletely understood. Here we use high-throughput, single-genome amplification and sequencing (HT-SGS) to sequence SARS-CoV-2 spike genes from people with HIV (PWH, n = 22) and people without HIV (PWOH, n = 25). In PWOH and PWH with CD4 T cell counts (i.e., CD4 counts) ≥ 200 cells/μL, we find that most SARS-CoV-2 genomes sampled in each person share one spike sequence. By contrast, in people with advanced HIV infection (i.e., CD4 counts < 200 cells/μL), HT-SGS reveals a median of 46 distinct linked groupings of spike mutations per person. Elevated intra-host spike diversity in people with advanced HIV infection is detected immediately after COVID-19 symptom onset, and early intra-host spike diversity predicts SARS-CoV-2 shedding duration among PWH. Analysis of longitudinal timepoints reveals rapid fluctuations in spike sequence populations, replacement of founder sequences by groups of new haplotypes, and positive selection at functionally important residues. These findings demonstrate remarkable intra-host genetic diversity of SARS-CoV-2 in advanced HIV infection and suggest that adaptive intra-host SARS-CoV-2 evolution in this setting may contribute to the emergence of new variants of concern.

Indexed as

COVID-19Evolution, MolecularHIV InfectionsSARS-CoV-2Spike Glycoprotein, CoronavirusAdultCD4 Lymphocyte CountFemaleGenetic VariationGenome, ViralHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationPhylogenySpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID39174553
PMCPMC11341811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.